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26% when patients were rated as “improved,” and 45%,
50%, respectively when rated as “much better.” Mean
7-point item scores improved by 0.46 points PANSS,
0.23 points QLS for “improved” patients, and by 0.88,
0.92, respectively for “much better” patients. Minimal
changes were seen for all items when patients were rated
as “unchanged.” The relationship between clinician rat-
ings and score changes was stable over multiple assess-
ments in this large sample. CONCLUSION: These data
describe the amount of change that represents clinically
important improvement related to treatment based on
commonly used symptom and QOL scales. Planning
sample sizes for clinical trials can be based on percentage
change in scores or mean item scores to aid clinicians and
researchers in understanding meaningful treatment ef-
fects.
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OBJECTIVES: The MSQ (Migraine Specific Quality of
Life Questionnaire) measures migraine-related quality of
life in three dimensions [Role Restrictive (RR), Role Pre-
ventive (RP), and Emotional Function (EF)]. The objec-
tive of this analysis was to compare the psychometric
properties of the Finnish (FN), Dutch (HD), Hungarian
(HG), Spanish (SP), and UK English translations with the
original US English version of the MSQ. METHODS:
One hundred and ninety-eight Finns, 127 Dutch, 169
Hungarians, 116 New Zealanders, and 169 Spaniards,
participated in a multinational migraine clinical trial in
which the MSQ was completed at baseline and after a 3-
month treatment period with customary therapy or
naratriptan 2.5 mg. The distribution of item responses,
item-discriminant validity and scale-level reliability for
the MSQ translations were examined and compared to
the previously published US English version results. RE-
SULTS: The distribution of responses for each item was
negatively skewed for all translations. The full range of
the response categories was used by migraineurs from all
countries except for the FN version in the clinical trial.
Every translation of the MSQ possessed item-scale corre-
lations that were higher for the hypothesized scale com-
pared to competing scales. Similar to the US English ver-
sion results, baseline Cronbach’s Alpha coefficients for
the three MSQ dimensions were greater than 0.82 for all
translations. The MSQ translations were sensitive to de-
tect intervention differences after 3 months of naratrip-
tan treatment for migraines. CONCLUSIONS: The MSQ
translations have demonstrated item-level discriminant
validity, reliability, and sensitivity to detect treatment
changes in quality of life and has cross-cultural empirical
validity. The MSQ is an effective tool in assessing mi-
graine-related quality of life across different cultures.
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OBJECTIVE: To evaluate the impact of schizophrenia
versus other chronic conditions on health-related quality
of life (HRQL). METHODS: Patients who were admitted
to a psychiatric inpatient unit at one of the 100 acute
care hospitals using the CQIsm Outcomes Measurement
System were administered the SF-36 health status survey.
All patients with a discharge diagnosis of schizophrenia
who completed the SF-36 and were admitted to adult
(n  233) or geropsychiatric (n  380) inpatient units
were selected. Randomly generated observations were
drawn from general US population SF-36 data to con-
struct two general population cohorts matching the adult
and geriatric schizophrenia samples, respectively, in dis-
tribution of age and gender. Adult and geriatric schizo-
phrenic cohorts were compared to their corresponding
matched general population cohort on each of the eight
SF-36 domains. Comparisons were also made to three
disease cohorts: Hypertension, Congestive Heart Failure
(CHF), and Diabetes. Independent sample t-tests were
used to evaluate differences between the groups. RE-
SULTS: Schizophrenic patients from both adult and geri-
atric groups had significantly lower scores (P  .001) on
virtually all mental and physical HRQL domains when
compared to the general US population and to patients
with hypertension or diabetes. Both groups of schizo-
phrenics scored lower (P  .001) on mental health do-
mains when compared to CHF patients. Adult schizo-
phrenics scored higher in the physical health domains
than CHF patients (P  .05), while geriatric schizophren-
ics were similar to CHF patients in those domains. CON-
CLUSIONS: Schizophrenia’s association with lower
HRQL extends beyond mental health to physical health
status. The physical health status of schizophrenics is
more impaired than those observed in patients with dia-
betes and hypertension, and is comparable to patients
with CHF.
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The perceived health status of individuals with severe
psychiatric illness, such as schizophrenia, is an important
element of disease burden and quality of life. The effect
of antipsychotic therapies on psychiatric symptoms is
well-understood. However, more information about the
effects of antipsychotics on health status is needed. OB-
JECTIVE: To examine changes in health-related quality
of life (HRQL) from inpatient admission to follow-up of
adult and geriatric patients with schizophrenia treated
with conventional or atypical antipsychotic agents.
METHODS: Data were obtained from the CQISM Out-
comes Measurement System, an ORYX (JCAHO) ac-
cepted performance improvement system, which tracks
patients admitted to adult or geropsychiatric inpatient
programs in over 100 general hospitals across 35 states.
Health status was measured by the SF-36 at time of ad-
mission and at three (geriatric) or six months (adult)
post-discharge. Patients with a primary discharge diagno-
sis of schizophrenia (ICD-9-CM codes 295.10–295.90)
who completed the SF-36 and were treated with antipsy-
chotic agents were included. One sample t-tests were
used to test the null hypothesis that the mean change is
equal to zero. RESULTS: Mean scores were higher (i.e.,
healthier) at follow-up, as compared to admission, on all
eight domains of the SF-36 for the adult schizophrenic
group (n  37) and seven of eight domains for the geriat-
ric schizophrenic group (n  38). Statistically significant
improvements were noted on five of the eight scales.
Largest improvements were found on Role Physical (P 
0.001), Role Emotional (P  0.001), and Social Func-
tioning (P  0.001). CONCLUSIONS: Marked improve-
ment in diverse aspects of HRQL among schizophrenic
patients treated with conventional or atypical antipsy-
chotic agents supports the humanistic value of antipsy-
chotic medications beyond simple symptom ameliora-
tion.
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OBJECTIVE: To describe the effect of depression on
health-related quality of life (HRQL) utilizing the SF-36
health status survey. The scores of patients with depres-
sion were compared to age and gender matched US popu-
lation norms and contrasted to results of similar research
on patients with other psychiatric disorders. METHODS:
SF-36 scores were collected from patients admitted to
adult (n  600) or geriatric (n  4439) psychiatric pro-
grams within acute care hospitals who had an ICD-9-CM
discharge diagnosis of depressive disorder. Adult and ge-
riatric US population norms were simulated using data
from the Medical Outcomes Study Manual and Interpre-
tation Guide to match the age and gender distributions of
the adult and geriatric depression groups. Admission SF-36
scores for the adult and geriatric depression groups were
compared to these age and gender matched US popula-
tion norms using independent sample t-tests. The find-
ings were then placed in context of SF-36 scores for other
psychiatric conditions including schizophrenia, bipolar
disorder, and cognitive disorder. RESULTS: HRQL for
both the adult and geriatric groups of depressed patients
was significantly lower than the simulated US population
norms for all eight domains of the SF-36, for physical
health as well as mental health (P  0.001). The greatest
differences were observed in the Role Physical, Social
Functioning, and Role Emotional domains. Adult inpa-
tients with depression had similar scores on all domains
to adult patients with the other psychiatric diagnoses
studied. However, geriatric patients with depression had
lower scores on HRQL across all domains versus geriat-
ric patients with other psychiatric illnesses. CONCLU-
SIONS: Depression has a strong negative association
with both adult and geriatric patients’ perceived HRQL.
Depressed patients not only had the expected decreases
on mental health domains, but also scored significantly
lower on physical health domains. Finally, depression in
geriatric patients is associated with greater decrements in
HRQL than other psychiatric illnesses examined.
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Currently there are no published studies comparing the
health-related quality of life (HRQoL) of transformed
and episodic migraneurs. OBJECTIVES: The study objec-
tive was to detect differences in HRQoL between patients
with transformed migraine (TM) and episodic migraine
(EM). METHODS: This retrospective study examined
the HRQoL of transformed and episodic migraneurs of
the Jefferson Headache Center during their first visit to
the center. Data collected included the Short Form 36
(SF-36) and the Migraine Disability Assessment (MIDAS)
questionnaires as well as demographic information. A
t-test with Bonferroni correction was used to test for sig-
nificant differences in the SF-36 domains between the
groups. RESULTS: To date, data has been collected on
62 patients, 31 from each group. There were no signifi-
cant differences with respect to gender, race, age or the
number of comorbid conditions between groups. Over
the last 90 days prior to their first visit, patients with TM
reported having a headache on an average of 77 days
compared to EM patients who averaged 18 days with
headache (P  0.05). Compared to EM patients, patients
with TM had statistically and clinically significant (5
point difference) lower mean scores on the mental com-
